Teva Seeks To Invalidate Insomnia Drug IP In Neurim Suit
Teva has hit back at Neurim's lawsuit accusing the generic giant of infringing its patent for an insomnia treatment, arguing that its fellow Israeli drugmaker's intellectual property is invalid....To view the full article, register now.
Already a subscriber? Click here to view full article